Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018 . Monaldi Arch Chest Dis [Internet]. 2021 Jan. 14 [cited 2025 Jun. 12];91(1). Available from: https://www.monaldi-archives.org/macd/article/view/1649